|
|
- 2016
ABCB1、CYP3A5和PON1基因多态性对氯吡格雷临床疗效的影响
|
Abstract:
摘要：目的 采用Meta分析方法评价冠心病患者肠道多药耐药蛋白1基因ABCB1、细胞色素P450基因CYP3A5、对氧磷酶-1基因PON1多态性与氯吡格雷疗效的关系。方法 计算机检索PubMed及中国知网数据库到2015年3月6日为止的中英文相关文献。采用Stata 12.0软件进行Meta分析。结果 共纳入35项研究，共32675例患者。分别有19项和8项研究报道了ABCB1 C3435T、CYP3A5 A6986G与氯吡格雷疗效的关系。Meta分析结果显示，ABCB1 C3435T和CYP3A5 A6986G多态性对患者主要心血管不良事件(MACE)的发生没有影响(OR=1.099，95% CI 0.913，1.323，P=0.319；OR=0.844，95% CI 0.784，1.220，P=0.844)。有19项关于PON1多态性的研究，发现Q192R突变与MACE的发生风险有关(OR=0.812，95% CI 0.671，0.984，P=0.033)，但敏感性分析结果显示缺乏稳定性。结论 PON1 Q192R突变可作为冠心病患者接受氯吡格雷治疗后不良心血管事件发生的危险因素，但需要更多高质量的研究证实。
ABSTRACT: Objective To investigate the relationship of the polymorphisms of ABCB1, CYP3A5 and PON1 with clopidogrel response in patients with coronary heart disease. Methods We searched the PubMed and CNKI databases for related studies published up to March 6, 2015. Stata 12.0 software was employed to perform the Meta-analysis. Results A total of 35 studies involving 32675 patients were analyzed. Nineteen and eight researches reported the correlation of ABCB1 C3435T and CYP3A5 A6986G with clopidogrel response, respectively, but no correlation was found (OR=1.099, 95% CI 0.913, 1.323, P=0.319; OR=0.844, 95% CI 0.784, 1.220, P=0.844). Nineteen studies examined PON1 polymorphisms, and Q192R mutation was found to be related to the risk of major adverse cardiovascular events (OR=0.812, 95% CI 0.671, 0.984, P=0.033). However, the result of sensitivity analysis showed lack of robustness. Conclusion PON1 Q192R mutation is a risk factor for MACE in patients treated with clopidogrel. Future large-scale studies that include long-term follow-ups are still needed
| [1] | VIVIANI ANSELMI C, BRIGUORI C, RONCARATI R, et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease[J]. JACC Cardiovasc Interv, 2013, 6(11):1166-1175. |
| [2] | SUH JW, KOO BK, ZHANG SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel[J]. CMAJ, 2006, 174(12):1715-1722. |
| [3] | SIMON T, VERSTUYFT C, MARY-KRAUSE M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med, 2009, 360(4):363-375. |
| [4] | SPIEWAK M, MALEK LA, KOSTRZEWA G, et al. Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes[J]. Kardiol Pol, 2009, 67(8):827-834. |
| [5] | 洪丹丹. 细胞色素P450酶(CYP2C19与CYP3A5)基因多态性对氯吡格雷治疗冠状动脉粥样硬化性心脏病患者疗效的影响[D]. 福建医科大学硕士学位论文, 2009. |
| [6] | TIROCH KA, SIBBING D, KOCH W, et al. Protective effect of the CYP2C19？？* 17 polymorphism with increased activation of clopidogrel on cardiovascular events[J]. Am Heart J, 2010, 160(3):506-512. |
| [7] | WALLENTIN L, JAMES S, STOREY RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial[J]. Lancet, 2010, 376(9749):1320-1328. |
| [8] | BOUMAN HJ, SCHOMIG E, VAN WERKUM JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy[J]. Nat Med, 2011, 17(1):110-116. |
| [9] | CAMPO G, FERRARESI P, MARCHESINI J, et al. Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention[J]. J Thromb Haemost, 2011, 9(10):2106-2108. |
| [10] | TRENK D, HOCHHOLZER W, FROMM MF, et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement[J]. Circ Cardiovasc Genet, 2011, 4(4):429-436. |
| [11] | TAUBERT D, VON BECKERATH N, GRIMBERG G, et al. Impact of P-glycoprotein on clopidogrel absorption[J]. Clin Pharmacol Ther, 2006, 80(5):486-501. |
| [12] | HULOT JS, COLLET JP, CAYLA G, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients[J]. Circ Cardiovasc Interv, 2011, 4(5):422-428. |
| [13] | JEONG YH, TANTRY US, KIM IS, et al. Effect of CYP2C19？？*2 and ？？*23 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin[J]. Circ-Cardiovasc Interv, 2011, 4(6):585-594. |
| [14] | SAAD AA, ABD ELSALAM AM, KAMAL GM, et al. Effect of cytochrome P450 3A5 polymorphism on platelet reactivity after treatment with clopidogrel in patients scheduled for percutaneous coronary intervention[J]. Egypt Heart J, 2011, 63(1):23-31. |
| [15] | WU H, QIAN J, XU J, et al. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China[J]. Pharmacogenet Genom, 2012, 22(12):887-890. |
| [16] | 丁肖梁. 冠心病患者氯吡格雷抗血小板活性个体差异影响因素的研究[D]. 苏州大学硕士论文, 2012. |
| [17] | 孙彬. 氯吡格雷治疗患者的血小板功能差异与遗传多态性研究[D]. 中国人民解放军医学院硕士论文, 2012. |
| [18] | 吴鸿谊. 急性冠脉综合征患者的血小板功能评价及氯吡格雷疗效的基因学研究[D]. 复旦大学博士论文, 2012. |
| [19] | TANG XF, WANG J, ZHANG JH, et al. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention[J]. Eur J Clin Pharmacol, 2013, 69(5):1103-1112. |
| [20] | VERSCHUREN JJ, BODEN H, WESSELS JA, et al. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction[J]. Int J Cardiol, 2013, 167(6):2882-2888. |
| [21] | 陈涛. 中国ACS患者氯吡格雷代谢相关基因多态性分布及其与近期临床终点的关联[D]. 北京协和医学院博士学位论文, 2013. |
| [22] | 周超飞. 基因多态性和氯吡格雷血药浓度对个体反应性差异和临床事件的影响研究[D]. 中国人民解放军医学院硕士学位论文, 2013. |
| [23] | MARTINEZ-QUINTANA E, MEDINA-GIL JM, RODRIGUEZ-GONZALEZ F, et al. Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants[J]. J Clin Pharmacol, 2014, 54(8):843-849. |
| [24] | ZHANG JH, TANG XF, ZHANG Y, et al. Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction[J]. Thromb Res, 2014, 134(5):970-975. |
| [25] | 白莹. 急性冠脉综合征患者氯吡格雷代谢基因多态性与抗血小板功能的注册研究[D]. 北京协和医学院博士学位论文, 2014. |
| [26] | 陈艳. 湘南地区汉族人群中PON1 Q192R基因多态性与氯吡格雷抵抗的相关性[D]. 南华大学硕士学位论文, 2014. |
| [27] | 唐晓芳. 冠心病患者氯吡格雷低反应性药物基因组学及药物效应动力学的研究[D]. 北京协和医学院博士学位论文, 2014. |
| [28] | 王辰. ACS患者氯吡格雷治疗敏感性评价及与基因多态性研究[D]. 皖南医学院硕士学位论文, 2014. |
| [29] | DALY PL, BECKER RC. Pharmacogenetics of antiplatelet therapy[J]. Curr Atheroscler Rep, 2014, 16(5):411. |
| [30] | BHATTACHARYYA T, NICHOLLS SJ, TOPOL EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk[J]. JAMA, 2008, 299(11):1265-1276. |
| [31] | LUO M, LI J, XU X, et al. ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis[J]. Thromb Res, 2012, 129(6):754-759. |
| [32] | SINGH M, SHAH T, ADIGOPULA S, et al. CYP2C19？？*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?[J]. Indian Heart J, 2012, 64(4):341-352. |
| [33] | SU J, XU J, LI X, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis[J]. PLoS One, 2012, 7(10):e46366. |
| [34] | RENY JL, COMBESCURE C, DAALI Y, et al. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis[J]. J Thromb Haemost, 2012, 10(7):1242-1251. |
| [35] | LI P, BU SH, LU XT, et al. Relationships between PON1 Q192R polymorphism and clinical outcome of antiplatelet treatment after percutaneous coronary intervention: a meta-analysis[J]. Mol Biol Rep, 2014, 41(9):6263-6273. |
| [36] | SIMON T, VERSTUYFT C, MARY-KRAUSE M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med, 2009, 360(4):363-375. |
| [37] | PARK JJ, PARK KW, KANG J, et al. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents[J]. Int J Cardiol, 2013, 163(1):79-86. |
| [38] | MEGA JL, CLOSE SL, WIVIOTT SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis[J]. Lancet, 2010, 376(9749):1312-1319. |
| [39] | LEWIS JP, FISCH AS, RYAN K, et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response[J]. Clin Pharmacol Ther, 2011, 90(4):568-574. |
| [40] | SIMON T, STEG PG, BECQUEMONT L, et al. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction[J]. Clin Pharmacol Ther, 2011, 90(4):561-567. |
| [41] | DELANEY JT, RAMIREZ AH, BOWTON E, et al. Predicting clopidogrel response using DNA samples linked to an electronic health record[J]. Clin Pharmacol Ther, 2012, 91(2):257-263. |
| [42] | PARE G, ROSS S, MEHTA SR, et al. Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the clopidogrel in the unstable angina to prevent recurrent events trial and the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events[J]. Circ Cardiovasc Genet, 2012, 5(2):250-256. |
| [43] | PARK JJ, PARK KW, KANG J, et al. Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after percutaneous coronary intervention[J]. JACC, 2012, 60 B213. |
| [44] | SNOEP JD, HOVENS MM, EIKENBOOM JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis[J]. Am Heart J, 2007, 154(2):221-231. |
| [45] | CAMPO G, PARRINELLO G, FERRARESI P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship with gene polymorphisms and clinical outcome[J]. JACC, 2011, 57(25):2474-2483. |
